Oncology
8 articles
Pfizer lung cancer drug: 60% progression-free after five years
After five years, 60% of patients with a specific type of lung cancer treated with Pfizer's lorlatinib were still alive without their disease progressing, a dramatic finding compared to just 8% on the
Daraxonrasib Doubles Survival in Pancreatic Cancer Treatment Trials
In a recent clinical trial, patients with advanced pancreatic cancer receiving Daraxonrasib lived more than twice as long as those on standard chemotherapy.
Peptide craze hype faces scientific and practical hurdles
Only 1 in 12 patients prescribed GLP-1 treatment remain on the medication after three years, according to data from Prime Therapeutics .
Legend Biotech stock surges on strong Q1 CAR T-cell therapy results
Legend Biotech's stock recently jumped 42% following new data, propelled by early clinical successes in difficult-to-treat cancers and robust sales of its existing CAR-T therapy, CARVYKTI, according t
Revolution Medicines' Experimental Pancreatic Cancer Drug Shows Promise
Revolution Medicines' experimental drug daraxonrasib doubled the median overall survival for patients with metastatic pancreatic cancer to 13.2 months in its pivotal Phase 3 trial.
BioNTech, Pfizer Share Bispecifics Data at ASCO
BioNTech's BNT142 achieved 7 RECIST 1.
Bristol Myers Squibb shows strong multiple myeloma data
In a significant development for multiple myeloma patients, Bristol Myers Squibb's mezigdomide triplet demonstrated a median progression-free survival of 18 months, more than doubling the 8.
FDA advisory panel rejects AstraZeneca breast cancer drug
A U.S. Food and Drug Administration advisory committee voted 3 to 6 against the benefit-risk profile of AstraZeneca's breast cancer drug camizestrant, according to AstraZeneca . This decision creates